GlassScriptPhysician profile
Jasmine Jacobs
NPI 1891204152
$2,816.09
in general payments reported to CMS, 2019-2025
20 companies · $20.62 in 2025
The $20.62 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,230 · 2022: $872 · 2023: $694 · 2025: $20.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.46 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $403.27 | 2021-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $301.54 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $295.82 | 2021-2023 | |
| Alkermes, INC. | $271.24 | 2021-2023 | Aristada, Lybalvi |
| Bausch Health US, LLC | $225.52 | 2021-2023 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $192.46 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $174.91 | 2021-2023 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $171.57 | 2021-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $128.84 | 2021-2023 | Spravato |
| Merck Sharp & Dohme LLC | $122.00 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $111.62 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $106.62 | 2021 | |
| Lundbeck LLC | $75.63 | 2021-2023 | Rexulti |
| Corium, LLC | $72.79 | 2022 | |
| Adlon Therapeutics L.P. | $40.13 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $38.31 | 2021 | |
| Axsome Therapeutics, INC. | $32.73 | 2023 | Auvelity |
| Almatica Pharma LLC | $19.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.77 | 2023 | Qelbree |
| Eisai INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.